Anna Del Llano
Business Development Manager
Lausanne, Switzerland - July 22, 2020 - Saphetor SA, a Swiss precision-medicine company and leader in diagnostic and bioinformatics solutions for clinical Next Generation Sequencing (NGS), announced today a distribution agreement with ELTA 90 Medical Science. Saphetor’s VarSome Clinical, a clinically-certified platform for interpretation of NGS data extends Elta’s portfolio of tools and services for a wide range of its clients employing NGS technologies for clinical as well as for research purposes.
Milan Milicevic, General Manager at Elta 90 Medical Science said: ‘ELTA 90 is always trying to bring best in class products to our respected customers, therefore we are very excited to announce collaboration with VarSome, and start a new chapter in molecular diagnostics.’
Tomas Kucera, Head of Business Development of Saphetor SA, commented: ‘We are pleased to welcome ELTA 90 Medical Science among our regional distributors for our bioinformatics tools. We are looking forward to working closely with their team to provide clients with an integrated solution for diagnostics purposes.’
About ELTA 90 Medical Science
ELTA 90 is a regional leader in the distribution of medical equipment and laboratory consumables. With more than 20 years of experience, ELTA became a recognizable partner who takes care of customers' needs.
About Saphetor SA
Saphetor SA, is a Swiss precision-medicine company dedicated to large-scale identification and interpretation of human genetic variants by leveraging proprietary algorithms and expert domain knowledge. Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions both for clinicians and researchers. VarSome.com search engine and professional community is freely accessible, featuring a widely-recognized community-driven knowledge base that enables flexible queries across more than 50 genetic and genomic data resources. VarSome Clinical is a clinically-accredited platform allowing fast and accurate variant discovery, annotation, and interpretation of NGS data for whole genomes, exomes, and gene panels, which helps clinicians reach faster and more accurate diagnoses and treatment decisions for genetic conditions.